Altimmune CEO Vipin Garg to step down Jan 1, 2026; Chairman Jerome Durso named successor

Altimmune, Inc.

Vipin Garg transitions from President/CEO to advisor through June 30, 2026; remains on board until Jan 31, 2026.
Jerome Durso, current Chairman and former Intercept CEO, becomes President and CEO effective Jan 1, 2026.
Durso receives annual base salary of $725,000, target bonus 60% of base, and equity grants of 633,700 RSUs and 1,824,400 stock options.
Garg will receive severance: 12 months base salary, COBRA subsidy, continued equity vesting through separation date.
Altimmune expects End-of-Phase 2 FDA meeting this quarter and 48-week IMPACT data before year-end for pemvidutide in MASH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.